海外の治験の状況「1」での検索結果
2039件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Do sulphponylureas preserve cortical function during hypoglycaemia in patients with type 1 diabetes and hypoglycaemia unawareness? - Do Sulphonylureas preserve cortical function during hypoglycaemia?
- We are testing the hypothesis that closing the K ATP channels using sulphonylureas (glibenclamide) during experimental insulin induced hypoglycaemia can help retain cerebral function and help enhance symptoms of hypoglycaemia in those with type 1 diabetes and hypoglycaemia unawareness. MedDRA version: 9.1 Level: LLT Classification code 10020997 Term: Hypoglycaemia unawareness MedDRA version: 9.1 Level: LLT Classification code 10012608 Term: Diabetes mellitus insulin-dependent
- United Kingdom
- 2007-03-09
Authorised
- Prévention du cancer du sein par le létrozole chez la femme ménopausée porteuse d'une mutation brca 1/2 - LIBER
- femmes porteuses d’une mutation des gènes BRCA1 ou 2 MedDRA version: 9.1 Level: LLT Classification code 10006190 Term: Breast cancer invasive NOS
- France
- 2007-02-23
Authorised
- A Phase 1, Single-Centre, Single-blind, CPO Solution Human Patch Test in Healthy Subjects
- Not Applicable (Healthy Volunteer Study)
- United Kingdom
- 2005-12-19
Authorised
- A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1
- Chronic Hepatitis C MedDRA version: 9.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis C MedDRA version: 9.1 Level: PT Classification code 10019744 Term: Hepatitis C MedDRA version: 9.1 Level: SOC Classification code 10021881 Term: Infections and infestations MedDRA version: 9.1 Level: SOC Classification code 10019805 Term: Hepatobiliary disorders
- Belgium, France, Germany, Italy, Netherlands, Portugal, Spain, United Kingdom
- 2008-06-19
Authorised
- A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CD5024 1% CREAM TREATMENT FOR UP TO 52 WEEKS IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA
- PATIENTS WITH PAPULOPUSTULAR ROSACEA MedDRA version: 9.1 Level: LLT Classification code 10039218 Term: Rosacea
- Bulgaria, Czech Republic, France, Germany, Hungary, Iceland
- 2008-05-19
Authorised
- Plasma Pharmacokinetics study of CD5024 1% cream in subjects with papulopustular rosacea
- PAPULOPUSTULAR ROSACEA MedDRA version: 9.1 Level: LLT Classification code 10039218 Term: Rosacea
- France, Germany, Hungary
- 2008-05-19
Authorised
- A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to less than 6 Years Old) Subjects with Congenital FXIII A-subunit Deficiency
- Congenital FXIII A-subunit Deficiency MedDRA version: 13.1 Level: PT Classification code 10016083 Term: Factor XIII deficiency System Organ Class: 10010331 - Congenital, familial and genetic disorders
- United Kingdom
- 2010-07-07
Authorised
- Incretin-based therapy in preclinical type 1 diabetes in adults.
- Type 1 diabetes MedDRA version: 18.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Finland
- 2015-11-05
Authorised
- Imaging with a radioactively-labeled antibody against PDL-1 in patients with lymphoma
- Diffuse large B-cell Lymphoma MedDRA version: 20.0 Level: HLT Classification code 10012819 Term: Diffuse large B-cell lymphomas System Organ Class: 100000004851 MedDRA version: 20.0 Level: PT Classification code 10012818 Term: Diffuse large B-cell lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10012820 Term: Diffuse large B-cell lymphoma NOS System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Netherlands
- 2018-09-26
Authorised
- Liraglutide in type 1 diabetes - A randomised, double-blind, placebo-controlled, parallel group, multi-centre trial of 242 liraglutide treatment in subjects with newly-diagnosed type 1 diabetes (The NewLira Study)
- The effect of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment. Also to investigate the effect on postprandial glucagon levels following sustacal meal test, HbA1c, insulin dose, self-monitored blood glucose profile,frequency of hypoglycaemic events, fasting and postprandial cholesterol profile, weight, waist circumference and quality of life. . MedDRA version: 16.1 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Denmark
- 2013-01-17